Clinical Trial

Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent

Study acronym: OPTIMIZE-APT
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Objectives: To assess the safety of tailored antiplatelet therapy (short DAPT followed by P2Y12 inhibitor alone strategy) in patients who received optimized DES implantation guided by intravascular imaging (IVUS or OCT) Hypothesis: Tailored antiplatelet strategy (short DAPT followed by P2Y12 inhibitor alone) is superior to conventional antiplatelet strategy in terms of clinically relevant bleeding and noninferior for ischemic composite adverse events in patients who received intravascular imaging-guided optimized DES implantation. (Optimized stent evaluated by on-site IVUS/OCT could act as an essential criterion for decision making for tailored antithrombotic strategy)
Protocol Amendment History 4 changes
critical Primary endpoint(s) modified 2026-08-14
notable Trial sites expanded: 25 -> 33 locations 2026-06-26
notable Primary completion pushed: 2027-08-30 -> 2027-12-31 2026-06-26
minor Completion pushed: 2028-12-31 -> 2032-12-31 2026-06-26
Trial Details
NCT Number NCT05418556
Lead Sponsor Asan Medical Center
Conditions Coronary Artery Disease
Enrollment 3,944 participants
Start Date 2022-10-21
Primary Completion 2027-12-31 (estimated)
Study Completion 2032-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-13